151 related articles for article (PubMed ID: 21371568)
1. Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model.
Wong MY; Chiu GN
Nanomedicine; 2011 Dec; 7(6):834-40. PubMed ID: 21371568
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous liposomal delivery of quercetin and vincristine for enhanced estrogen-receptor-negative breast cancer treatment.
Wong MY; Chiu GN
Anticancer Drugs; 2010 Apr; 21(4):401-10. PubMed ID: 20110806
[TBL] [Abstract][Full Text] [Related]
3. The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells.
Huang J; Wang S; Lyu H; Cai B; Yang X; Wang J; Liu B
Mol Cancer; 2013 Nov; 12(1):134. PubMed ID: 24215614
[TBL] [Abstract][Full Text] [Related]
4. Co-delivery of vincristine and quercetin by nanocarriers for lymphoma combination chemotherapy.
Zhu B; Yu L; Yue Q
Biomed Pharmacother; 2017 Jul; 91():287-294. PubMed ID: 28463792
[TBL] [Abstract][Full Text] [Related]
5. Optimization of vincristine-topotecan combination--paving the way for improved chemotherapy regimens by nanoliposomes.
Zucker D; Barenholz Y
J Control Release; 2010 Sep; 146(3):326-33. PubMed ID: 20685223
[TBL] [Abstract][Full Text] [Related]
6. Liposome co-encapsulation of synergistic combination of irinotecan and doxorubicin for the treatment of intraperitoneally grown ovarian tumor xenograft.
Shaikh IM; Tan KB; Chaudhury A; Liu Y; Tan BJ; Tan BM; Chiu GN
J Control Release; 2013 Dec; 172(3):852-61. PubMed ID: 24459693
[TBL] [Abstract][Full Text] [Related]
7. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.
Cufi S; Corominas-Faja B; Vazquez-Martin A; Oliveras-Ferraros C; Dorca J; Bosch-Barrera J; Martin-Castillo B; Menendez JA
Oncotarget; 2012 Apr; 3(4):395-8. PubMed ID: 22565037
[TBL] [Abstract][Full Text] [Related]
8. Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.
Raja SM; Clubb RJ; Ortega-Cava C; Williams SH; Bailey TA; Duan L; Zhao X; Reddi AL; Nyong AM; Natarajan A; Band V; Band H
Cancer Biol Ther; 2011 Jan; 11(2):263-76. PubMed ID: 21088503
[TBL] [Abstract][Full Text] [Related]
9. Monitoring Src status after dasatinib treatment in HER2+ breast cancer with
McKnight BN; Viola-Villegas NT
Breast Cancer Res; 2018 Oct; 20(1):130. PubMed ID: 30359299
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance.
Barok M; Isola J; Pályi-Krekk Z; Nagy P; Juhász I; Vereb G; Kauraniemi P; Kapanen A; Tanner M; Vereb G; Szöllösi J
Mol Cancer Ther; 2007 Jul; 6(7):2065-72. PubMed ID: 17620435
[TBL] [Abstract][Full Text] [Related]
11. Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy.
Fujimoto-Ouchi K; Sekiguchi F; Yamamoto K; Shirane M; Yamashita Y; Mori K
Cancer Chemother Pharmacol; 2010 Jul; 66(2):269-76. PubMed ID: 19904537
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.
Barok M; Tanner M; Köninki K; Isola J
Breast Cancer Res; 2011 Apr; 13(2):R46. PubMed ID: 21510863
[TBL] [Abstract][Full Text] [Related]
13. The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity.
Dragowska WH; Weppler SA; Qadir MA; Wong LY; Franssen Y; Baker JH; Kapanen AI; Kierkels GJ; Masin D; Minchinton AI; Gelmon KA; Bally MB
BMC Cancer; 2011 Oct; 11():420. PubMed ID: 21961653
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan.
Riviere K; Kieler-Ferguson HM; Jerger K; Szoka FC
J Control Release; 2011 Aug; 153(3):288-96. PubMed ID: 21600250
[TBL] [Abstract][Full Text] [Related]
15. Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octasulfate as drug trapping agent.
Liu J; Chi D; Pan S; Zhao L; Wang X; Wang D; Wang Y
Int J Pharm; 2019 Feb; 557():264-272. PubMed ID: 30599233
[TBL] [Abstract][Full Text] [Related]
16. Dual agent loaded PLGA nanoparticles enhanced antitumor activity in a multidrug-resistant breast tumor eenograft model.
Chen Y; Zheng XL; Fang DL; Yang Y; Zhang JK; Li HL; Xu B; Lei Y; Ren K; Song XR
Int J Mol Sci; 2014 Feb; 15(2):2761-72. PubMed ID: 24552875
[TBL] [Abstract][Full Text] [Related]
17. Thermo-Sensitive Liposome co-Loaded of Vincristine and Doxorubicin Based on Their Similar Physicochemical Properties had Synergism on Tumor Treatment.
Li M; Li Z; Yang Y; Wang Z; Yang Z; Li B; Xie X; Song J; Zhang H; Li Y; Gao G; Yang J; Mei X; Gong W
Pharm Res; 2016 Aug; 33(8):1881-98. PubMed ID: 27075873
[TBL] [Abstract][Full Text] [Related]
18. Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.
O'Donovan N; Byrne AT; O'Connor AE; McGee S; Gallagher WM; Crown J
Invest New Drugs; 2011 Oct; 29(5):752-9. PubMed ID: 20229355
[TBL] [Abstract][Full Text] [Related]
19. V-ATPase inhibition overcomes trastuzumab resistance in breast cancer.
von Schwarzenberg K; Lajtos T; Simon L; Müller R; Vereb G; Vollmar AM
Mol Oncol; 2014 Feb; 8(1):9-19. PubMed ID: 24055142
[TBL] [Abstract][Full Text] [Related]
20. Tyroservatide-TPGS-paclitaxel liposomes: Tyroservatide as a targeting ligand for improving breast cancer treatment.
Jin X; Li M; Yin L; Zhou J; Zhang Z; Lv H
Nanomedicine; 2017 Apr; 13(3):1105-1115. PubMed ID: 27845234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
